Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Cannabinoid [EPC]
Dronabinol is a synthetic cannabinoid and a Schedule III controlled substance used primarily to treat chemotherapy-induced nausea and vomiting (CINV) and AIDS-related anorexia. It acts as an agonist at cannabinoid receptors to stimulate appetite and reduce emesis.
Name
Dronabinol
Raw Name
DRONABINOL
Category
Cannabinoid [EPC]
Drug Count
3
Variant Count
23
Last Verified
February 17, 2026
RxCUI
197635, 197636, 197634, 205641, 205642, 205645, 1928948, 1928954
UNII
7J8897W37S
About Dronabinol
Dronabinol is a synthetic cannabinoid and a Schedule III controlled substance used primarily to treat chemotherapy-induced nausea and vomiting (CINV) and AIDS-related anorexia. It acts as an agonist at cannabinoid receptors to stimulate appetite and reduce emesis.
Detailed information about Dronabinol
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Dronabinol.
Dronabinol is a synthetic form of delta-9-tetrahydrocannabinol (Δ9-THC), the primary psychoactive constituent found in the Cannabis sativa L. plant. It belongs to the pharmacological class known as cannabinoids [EPC]. In the clinical setting, Dronabinol is utilized as an antiemetic (a drug that prevents vomiting) and an orexigenic (an appetite stimulant). The U.S. Food and Drug Administration (FDA) first approved Dronabinol in 1985 under the brand name Marinol, initially for the treatment of nausea and vomiting associated with cancer chemotherapy. In 1992, its indications were expanded to include the treatment of anorexia associated with weight loss in patients with Acquired Immunodeficiency Syndrome (AIDS). Unlike botanical cannabis, which contains a complex mixture of hundreds of compounds, Dronabinol is a single-isomer, highly purified synthetic compound, allowing for standardized dosing and predictable pharmacological activity.
The therapeutic effects of Dronabinol are mediated through its interaction with the endogenous cannabinoid system (ECS), a complex cell-signaling system that plays a crucial role in regulating a wide range of functions, including mood, appetite, pain sensation, and immune response. Dronabinol acts as a partial agonist at two primary types of G-protein coupled receptors: CB1 and CB2.
At the molecular level, when Dronabinol binds to these receptors, it inhibits the enzyme adenylate cyclase and modulates ion channels (specifically calcium and potassium channels), leading to a reduction in neuronal excitability and the modulation of neurotransmitter release (such as glutamate and GABA).
Understanding the pharmacokinetics of Dronabinol is essential for optimizing therapy and managing potential side effects. The drug exhibits complex behavior due to its high lipophilicity (fat solubility).
Dronabinol is FDA-approved for two specific clinical indications where conventional treatments have failed or are insufficient:
Off-Label Uses: While not FDA-approved for these conditions, some healthcare providers may prescribe Dronabinol off-label for chronic pain management, obstructive sleep apnea, or certain types of tremors, although clinical evidence for these uses is often limited or conflicting.
Dronabinol is available in several formulations to accommodate different patient needs:
> Important: Only your healthcare provider can determine if Dronabinol is right for your specific condition. The choice of formulation and dosage must be individualized based on the patient's clinical response and tolerance.
Dosing of Dronabinol must be carefully individualized, as the therapeutic window is narrow and patient response varies significantly.
The safety and effectiveness of Dronabinol in pediatric patients have not been established. While it has been used off-label in some pediatric oncology cases, there are no standardized FDA-approved dosing guidelines for children. Healthcare providers must weigh the potential benefits against the significant risks of CNS effects in developing brains.
The pharmacokinetics of Dronabinol have not been extensively studied in patients with renal insufficiency. However, since renal excretion is a minor pathway for the parent drug, dosage adjustments may not be strictly required, though close monitoring for toxicity is essential.
Dronabinol is extensively metabolized by the liver. Patients with hepatic impairment may experience increased plasma concentrations and prolonged half-lives of the drug. Healthcare providers should initiate therapy at the lowest possible dose and monitor closely for adverse effects.
Elderly patients (65 years and older) are more sensitive to the psychoactive and cardiovascular effects of cannabinoids. It is recommended to start at the lower end of the dosing range (e.g., 2.5 mg once daily for anorexia) and titrate slowly while monitoring for confusion, dizziness, or falls.
If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not double the dose to catch up, as this increases the risk of significant CNS depression or psychosis.
Signs of Dronabinol overdose include severe drowsiness, euphoria, heightened sensory awareness, altered time perception, reddened eyes, dry mouth, tachycardia (rapid heart rate), and orthostatic hypotension (dizziness upon standing). In severe cases, panic attacks, hallucinations, or seizures may occur.
In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention immediately. Treatment is primarily supportive, focusing on maintaining airway patency and managing cardiovascular stability.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as sudden discontinuation after prolonged use can lead to withdrawal symptoms.
Because Dronabinol is a psychoactive substance, side effects involving the central nervous system (CNS) are very common. These are often dose-related and may diminish as the patient develops tolerance over several days of therapy.
> Warning: Stop taking Dronabinol and call your doctor immediately if you experience any of these serious reactions.
With prolonged use, patients may develop a psychological or physical dependence on Dronabinol. Long-term effects can include:
No FDA black box warnings currently exist for Dronabinol. However, the FDA-approved labeling contains prominent warnings regarding psychiatric and hemodynamic (blood flow) instability. It is classified as a Schedule III controlled substance due to its potential for abuse and dependence.
Report any unusual symptoms to your healthcare provider. Monitoring of heart rate and mental status is typically recommended during the initiation of therapy.
Dronabinol is a potent psychoactive medication that requires careful medical supervision. It should only be used for the indications specifically approved by the FDA or as directed by a specialist. Patients should be aware that Dronabinol can significantly impair the mental and physical abilities required for driving or operating heavy machinery.
There are no FDA black box warnings for Dronabinol as of 2026. However, the medication carries significant warnings regarding its CNS effects and its potential for abuse.
Healthcare providers will typically monitor the following during Dronabinol therapy:
Patients should not drive, operate machinery, or engage in hazardous activities until it is established that they can tolerate Dronabinol and perform such tasks safely. The drug's effects on judgment and coordination can persist for several hours or even days after a dose.
Alcohol should be strictly avoided while taking Dronabinol. Alcohol can significantly increase the CNS depressant effects of cannabinoids, leading to severe sedation, respiratory depression, and increased risk of falls or accidents. Additionally, the oral solution (Syndros) contains 50% alcohol by volume.
Do not stop taking Dronabinol suddenly if you have been taking it for a long period. Abrupt discontinuation can lead to withdrawal symptoms such as irritability, sleep disturbances, and gastrointestinal distress. Your doctor will provide a tapering schedule to gradually reduce the dose.
> Important: Discuss all your medical conditions, especially heart disease, seizures, or mental health issues, with your healthcare provider before starting Dronabinol.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete review of your medication list is necessary to prevent dangerous interactions.
There are certain conditions and circumstances where Dronabinol must NEVER be used due to the risk of life-threatening complications:
In these cases, the healthcare provider must perform a careful risk-benefit analysis:
Patients who have had adverse psychiatric or allergic reactions to botanical cannabis (marijuana) are highly likely to experience similar or more intense reactions to Dronabinol. There is a direct cross-sensitivity between natural THC and synthetic Dronabinol.
> Important: Your healthcare provider will evaluate your complete medical history, including any history of allergies or mental health conditions, before prescribing Dronabinol.
Dronabinol is classified as Pregnancy Category C (under the older FDA system). There are no adequate and well-controlled studies in pregnant women. Animal studies have shown that THC can cross the placenta and may result in fetal growth restriction, skeletal abnormalities, and neurodevelopmental issues. Use during pregnancy should only be considered if the potential benefit justifies the potential risk to the fetus. It is generally recommended to avoid Dronabinol during pregnancy, especially in the first trimester.
Dronabinol and its metabolites are excreted in human milk. Cannabinoids can remain in breast milk for long periods. Because of the potential for serious adverse effects in the nursing infant (including developmental delays and sedation), the use of Dronabinol is generally not recommended for breastfeeding mothers. A decision should be made whether to discontinue nursing or discontinue the drug.
The safety and efficacy of Dronabinol in children have not been established. The pediatric brain is still developing, and the long-term impact of cannabinoid exposure on cognitive and emotional development is a significant concern. While it may be used in rare, refractory cases of pediatric CINV, this is always done under the strict guidance of a pediatric oncologist.
Clinical studies of Dronabinol did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, elderly patients are generally more sensitive to the effects of Dronabinol. They are at a higher risk for:
Dosage should be started at the lowest possible level and increased very slowly.
Specific studies in patients with renal impairment are lacking. However, since the drug is primarily metabolized by the liver and excreted in feces, renal impairment is not expected to significantly alter the clearance of the parent drug. Nevertheless, metabolites may accumulate, and patients should be monitored for increased toxicity.
Dronabinol is extensively metabolized by the liver. In patients with hepatic impairment (Child-Pugh Class A, B, or C), the clearance of Dronabinol may be reduced, leading to higher blood levels. Healthcare providers should use caution and consider longer dosing intervals or lower doses in these patients.
> Important: Special populations require individualized medical assessment and frequent monitoring to ensure safety and efficacy.
Dronabinol is an orally active cannabinoid which, like other cannabinoids, has complex effects on the central nervous system (CNS). It is a direct agonist at the CB1 and CB2 receptors. The antiemetic effect is believed to be caused by the activation of CB1 receptors in the dorsal vagal complex of the brainstem, which modulates the vomiting reflex. The appetite-stimulant effect is mediated through CB1 receptors in the hypothalamus and the mesolimbic reward system, enhancing the palatability of food and the drive to eat.
The effects of Dronabinol are dose-related. Low doses primarily produce appetite stimulation, while higher doses are required for antiemetic effects. The onset of action for appetite stimulation typically occurs within 30 to 60 minutes, with peak effects at 2 to 4 hours. The duration of action for CNS effects is generally 4 to 6 hours, although appetite stimulation can last for 24 hours or longer.
| Parameter | Value |
|---|---|
| Bioavailability | 10% - 20% (due to high first-pass metabolism) |
| Protein Binding | 97% - 99% (primarily to albumin) |
| Half-life (Terminal) | 25 - 36 hours (parent drug); longer for metabolites |
| Tmax | 0.5 - 4 hours |
| Metabolism | Hepatic (CYP2C9, CYP3A4) to active 11-OH-THC |
| Excretion | Fecal (35% - 50%), Renal (10% - 15%) |
Dronabinol is a synthetic cannabinoid and is classified therapeutically as an antiemetic and an appetite stimulant. It is a Schedule III controlled substance under the Controlled Substances Act, indicating a moderate to low potential for physical and psychological dependence.
Medications containing this ingredient
Common questions about Dronabinol
Dronabinol is primarily used for two FDA-approved indications: treating nausea and vomiting caused by cancer chemotherapy (CINV) and treating loss of appetite (anorexia) associated with weight loss in patients with AIDS. It is typically reserved for CINV patients who have not responded well to standard anti-nausea medications. By mimicking the effects of natural cannabinoids in the body, it helps stimulate the brain's hunger signals and suppress the vomiting reflex. Your doctor may also prescribe it off-label for other conditions, though this is less common. Always use this medication exactly as prescribed by your healthcare provider.
The most frequent side effects of Dronabinol involve the central nervous system, including dizziness, drowsiness, and a feeling of being 'high' (euphoria). Many patients also report feeling confused, paranoid, or excessively sleepy, especially when first starting the drug. Physical symptoms like dry mouth, rapid heartbeat, and stomach pain are also common. Most of these effects are dose-dependent and may lessen as your body adjusts to the medication over a few days. If these symptoms become severe or distressing, you should contact your healthcare provider immediately.
No, you should strictly avoid alcohol while taking Dronabinol. Alcohol can significantly worsen the side effects of Dronabinol, such as extreme drowsiness, dizziness, and impaired judgment, which increases the risk of accidents and falls. Furthermore, the liquid form of Dronabinol (Syndros) contains 50% alcohol, and combining it with more alcohol can lead to toxicity. Using alcohol with cannabinoids can also lead to unpredictable psychiatric reactions. Always discuss your lifestyle and substance use with your doctor before beginning treatment.
Dronabinol is generally not recommended during pregnancy unless the potential benefits clearly outweigh the risks to the fetus. Animal studies have indicated that THC can cross the placenta and may cause harm, including low birth weight and neurodevelopmental issues. There is insufficient data from human trials to confirm its safety for pregnant women. If you are pregnant or planning to become pregnant, you must discuss alternative treatments with your doctor. Breastfeeding is also discouraged while taking Dronabinol as the drug passes into breast milk.
The time it takes for Dronabinol to work can vary depending on the individual and whether it is taken for appetite or nausea. For appetite stimulation, patients usually notice an effect within 30 to 60 minutes, with the peak effect occurring between 2 and 4 hours after the dose. For nausea and vomiting, it is typically taken 1 to 3 hours before chemotherapy to ensure the drug is active in the system when needed. The effects generally last for about 4 to 6 hours, though appetite stimulation can persist much longer. Food intake can also delay or increase the absorption time.
You should not stop taking Dronabinol suddenly if you have been using it regularly for a long period. Abruptly stopping the medication can lead to withdrawal symptoms, which may include irritability, insomnia, restlessness, hot flashes, and sweating. These symptoms typically begin within 12 hours of the last dose and can last for several days. Your healthcare provider will usually recommend a gradual dose reduction (tapering) to safely discontinue the drug. Always follow the specific tapering schedule provided by your medical professional.
If you miss a dose of Dronabinol, take it as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take two doses at once to make up for the missed one, as this can lead to an overdose and severe psychoactive side effects. Consistency is important for the drug's effectiveness, especially for appetite stimulation. If you frequently miss doses, talk to your doctor about ways to help you remember your medication schedule.
Yes, weight gain is a primary goal of Dronabinol therapy when used for AIDS-related anorexia. The drug works by stimulating the appetite and increasing the desire to eat, which leads to higher caloric intake. In clinical trials, many patients experienced a significant increase in appetite and subsequent weight stabilization or gain. However, weight gain is not a guaranteed side effect for everyone, and it may take several weeks of consistent use to see a change in body weight. Your doctor will monitor your weight and nutritional status throughout the treatment.
Dronabinol can interact with many other medications, so it is vital to provide your doctor with a full list of everything you take. It can have dangerous interactions with CNS depressants like benzodiazepines, opioids, and sleep aids, leading to severe sedation. It also interacts with drugs metabolized by the liver enzymes CYP3A4 and CYP2C9, such as certain antifungals and antibiotics. Additionally, the liquid form can interact with disulfiram or metronidazole due to its alcohol content. Your pharmacist can check for specific drug-drug interactions before you start your first dose.
Yes, Dronabinol is available as a generic medication in capsule form, which is typically more cost-effective than the brand-name Marinol. Generic versions are required by the FDA to have the same active ingredient, strength, and effectiveness as the brand-name drug. The oral solution, Syndros, may not have a generic equivalent available in all regions yet. Availability of generics can vary by pharmacy and insurance plan. You should check with your pharmacist to see if a generic version is an option for your prescription.